Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody shot aimed at taming hepatitis b

NCT ID NCT05856890

Recruiting now Disease control Sponsor: Rockefeller University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a single dose of a new antibody (HepB mAb19) in 37 adults with chronic hepatitis B who are already on standard antiviral pills. The main goal is to see if the antibody is safe and how long it stays in the body. It is an early-phase trial, so it focuses on safety and drug levels, not yet on curing the infection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B HEPATITIS B VIRUS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Rockefeller University

    RECRUITING

    New York, New York, 10065, United States

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••